Cite

HARVARD Citation

    de Jong, E. et al. (2022). Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. International journal of cancer. 150 (10), pp. 1654-1663. [Online]. 
  
Back to record